Tonight we are delighted to welcome four companies CEO’s to our last live event of the year: Suzanne Dilly, CEO at ValiRx, Vincent Mascolo, CEO at Atlantic Lithium, Helge Hammer CEO at Longboat Energy and Bert Monro CEO at Coro Gold. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 457.50
Bid: 456.00
Ask: 457.50
Change: 16.00 (3.62%)
Spread: 1.50 (0.33%)
Open: 456.50
High: 461.00
Low: 451.00
Prev. Close: 441.50
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Hutchmed completes patient enrolment for cancer drug study

Hutchmed completes patient enrolment for cancer drug study

6 Dec 21 10:44

Two Hutchmed drugs included in China's 2022 reimbursement list

(Sharecast News) - Hutchmed China announced on Friday that, following negotiations with the China National Healthcare Security Administration (NHSA), from 1 January the updated National Reimbursement Drug List (NRDL) will continue to include 'Elunate', or fruquintinib, and would now include 'Sulanda', or surufatinib.

3 Dec 21 13:23

Two Hutchmed drugs included on China's state approved medicines list

Two Hutchmed drugs included on China's state approved medicines list

3 Dec 21 09:54

Hutchmed China shares rise on Orphathys and Tagrisso Phase 3 study

Hutchmed China shares rise on Orphathys and Tagrisso Phase 3 study

24 Nov 21 11:35

TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal

TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal

1 Nov 21 09:14

IN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug

IN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug

28 Oct 21 21:59

Hutchmed China sells joint venture stake for USD169 million

Hutchmed China sells joint venture stake for USD169 million

29 Sep 21 11:08

Hutchmed starts drug combination trial for neuroendocrine tumours

Hutchmed starts drug combination trial for neuroendocrine tumours

21 Sep 21 10:51

Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors

Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors

20 Sep 21 09:09

Hutchmed China's amdizalisib secures breakthrough therapy designation

Hutchmed China's amdizalisib secures breakthrough therapy designation

13 Sep 21 10:22

Hutchmed, Astra launch drug combination trial to treat lung cancer

Hutchmed, Astra launch drug combination trial to treat lung cancer

8 Sep 21 13:49

Hutchmed China to trade in Shanghai and Shenzhen through link scheme

Hutchmed China to trade in Shanghai and Shenzhen through link scheme

6 Sep 21 09:37

Hutchmed launches trial into drug combination to treat breast cancer

Hutchmed launches trial into drug combination to treat breast cancer

26 Aug 21 10:38

Hutchmed strikes collaboration deal with Epizyme

(Sharecast News) - Commercial-stage biotechnology company Hutchmed China announced a collaboration to research, develop, manufacture and commercialise 'Tazverik' in Greater China on Monday, including mainland China, Hong Kong, Macau and Taiwan.

9 Aug 21 12:35

Hutchmed to partner with Epizyme on tumour-targetting treatment

Hutchmed to partner with Epizyme on tumour-targetting treatment

9 Aug 21 10:06

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.